

Elevated blood pressure in the emergency department – a risk factor for incident cardiovascular disease: An EHR-based cohort study

P. Oras¹, H. Häbel², P. H. Skoglund³, P. Svensson¹

¹ Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden

²Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

³Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

Corresponding author: Pontus Oras
And reprints Södersjukhuset
118 83 Stockholm, Sweden
pontus.oras@stud.ki.se
Phone +46 766 555 444

Word count: 3,515

Tables: 3

Figures: 9

Trial registration no: ClinicalTrials.gov NCT03954119

Declaration of interest: The authors declare no conflict of interest.

Source of funding: The authors received no financial support for the study, authorship, and publication of this report.

Ethics committee approval: This study has been approved by the Regional Ethical Review Board in Stockholm. Ethical review number 2016/888-31.

ABSTRACT

Objectives: In the emergency department (ED), high blood pressure (BP) is commonly observed but mostly used to evaluate patients' health in the short-term. We aimed to study whether ED-measured BP is associated with incident atherosclerotic cardiovascular disease (ASCVD), myocardial infarction (MI), or stroke in long-term, and to estimate the number needed to screen (NNS) to prevent ASCVD.

Design: Electronic Health Records (EHR) and national register-based cohort study. The association between BP and incident ASCVD was studied with Cox-regression.

Setting: Two university hospital emergency departments in Sweden.

Data sources: BP data were obtained from EDs EHR, and outcome information was acquired through the Swedish National Patient Register for all participants.

Participants: All patients ≥ 18 years old who visited the EDs between 2010 to 2016, with an obtained BP (n=300,193).

Main outcome measures: Incident ASCVD, MI, and stroke during follow-up.

Results: The subjects were followed for a median of 42 months. 8,999 incident ASCVD events occurred (MI: 4,847, stroke: 6,661). Both diastolic and systolic BP (SBP) was associated with incident ASCVD, MI, and stroke with a progressively increased risk for SBP within hypertension grade 1 (HR 1.15, 95% CI 1.06 to 1.24), 2 (HR 1.35, 95% CI 1.25 to 1.47), and 3 (HR 1.63, 95% CI 1.49 to 1.77). The six-year cumulative incidence of ASCVD was 12% for patients with SBP ≥ 180 mmHg compared to 2% for normal levels. To prevent one ASCVD event during the median follow-up, NNS was estimated to 151, whereas NNT to 71.

Conclusions: BP in the ED is associated with incident ASCVD, MI, and stroke. High BP recordings in EDs should not be disregarded as isolated events, but an opportunity to detect and improve treatment of hypertension. ED-measured BP provides an important and under-

used tool with great potential to reduce morbidity and mortality associated with hypertension.

Keywords: blood pressure, emergency department, atherosclerotic cardiovascular disease, myocardial infarction, stroke, long-term.

INTRODUCTION

High blood pressure (BP) is a well-studied and established risk factor for cardiovascular disease (CVD)¹⁻³ and is commonly observed in the emergency department (ED).⁴

Hypertension accounts for nearly fifty per cent of the mortality in stroke and heart disease, and every year approximately 9.4 million cardiovascular deaths occur due to complications of hypertension, which makes hypertension the most important risk factor for disability and death worldwide.⁵

Finding and treating patients with hypertension is a priority in CVD prevention. Studies have shown that for every 10-20-mmHg reduction in systolic blood pressure (SBP), there is a substantial risk reduction for CVD,⁶⁻⁸ and that patients with higher BP levels benefit from more intensive drug intervention.⁹ However, a majority of the patients with high BP do not achieve BP control (BP < 140/90 mm Hg), and many are unaware of their condition.¹⁰

In the ED, BP is measured on almost every patient in order to assess the patient's condition and acuity^{11,12} regardless of the presenting chief complaint. Previous research has reported that up to one-third of the patients in the ED have BP levels above the threshold for hypertension, and severely elevated levels have been observed in 20 % of the cases.¹¹

Elevated BP in the ED can be explained by factors such as pain, anxiety or other stressors, which raises the question of its predictive value and if hypertension screening based on routine recordings in the ED are useful.⁴

Although the value of BP in the ED as hypertension screening can be questioned,¹³ it is not known if high BP in the ED is associated with incident atherosclerotic cardiovascular disease (ASCVD), nor the benefit on acting in this setting. Therefore, we aimed to examine if the first measured BP in the ED is associated with incident ASCVD, MI, or stroke during a long-time follow-up. We also aimed to assess the potential benefits of screening for patients with hypertension in the ED by estimating the number needed to screen and treat to prevent

ASCVD.

MATERIALS AND METHODS

Study design and setting

This electronic health records (EHR) and register-based cohort study included all patients who visited the EDs at Karolinska University Hospital in Solna and Huddinge, Sweden during the period from January 2010 until March 2016, with a BP measured in the ED. The exposure BP was obtained from EDs EHR, and all outcome information were acquired by linkage to national registers for all included participants. The participants were followed regarding incident disease, death or censoring until end of the study on 31st December 2016. The study was registered at ClinicalTrials.gov: NCT03954119.

Inclusion criteria

The study cohort was all patients visiting the EDs with a BP obtained at arrival. Patients were eligible for inclusion in the study disregarded of the chief complaint as long as they had a BP recorded and were older than 18 years old. Patients without a Swedish personal identification number were excluded since no outcome information could be obtained from these patients. Only the first visit in the ED with a measured BP was included. Recurrent BP measurements during hospitalisation or recurrent visits to the ED with new BP recordings were disregarded.

Data sources

BP data and all covariates were acquired through Karolinska University Hospital's EHR for each patient's ED visit. The National Board of Health and Welfare (NBHW) provided data for outcome events and event dates until the end of December 2016, from the National Patient Register for the selected subjects. Hypertension diagnosis before index visits were collected

from this register from the period January 1997 to December 2016. The cause of death and date of death were obtained through the NBHW's Cause of Death Register. Data for each subject in the registers were merged to one dataset by the unique pseudonymised identification number. Data for pick-up of prescribed drugs were acquired from the NBHW's Prescribed Drugs Register.

Exposure definitions

The exposures were defined as the first measured SBP and DBP in the ED; both measured as a part of the triage system according to clinical routine.¹² BP was categorised into groups due to no certain linear association for BP with the outcomes. The categories were based on the *ESC and ESH* classification of BP grades and the definition of hypertension grades.¹⁴ SBP categories were defined as <90 mmHg, 90-119 mmHg, 120-129 mmHg, 130-139 mmHg, 140-159 mmHg, 160-179 mmHg, and >179 mmHg. DBP were categorised into <60 mmHg, 60-79 mmHg, 80-84 mmHg, 85-89 mmHg, 90-99 mmHg, 100-109 mmHg, and >110 mmHg (Supplementary Table 1).

Endpoint definitions

The composited primary endpoint was ASCVD, defined as the first occurring event of CHD death (fatal MI and sudden cardiac death), non-fatal MI and all-cause stroke, based on the pooled cohort risk equations.¹⁵ Secondary endpoints were fatal and non-fatal MI, all-cause stroke, ischemic stroke, and intracerebral haemorrhage. Data for endpoints were derived as the primary diagnosis from the National Patient Register and Cause of Death Register, according to the *International Classification of Diseases 10th edition*¹⁶ (ICD-10). ICD-10 classification for ASCVD was fatal CHD (MI: I210-I214, I219, I220, I221, I228, I229, sudden cardiac death: I461 or I469), non-fatal MI (I210-I214, I219, I220, I221, I228 or I229),

fatal and non-fatal ischemic stroke (I630-I635, I638 or I639) (Supplementary Table 2). Only the first event that occurred in the follow-up period was included in the endpoint ASCVD, and all following recurrent events were disregarded. Secondary endpoints were defined as fatal and non-fatal MI (I210-I214, I219, I220, I221, I228 or I229. I200 were included if combined with intervention procedure codes FNA-FNG, FNW), all-cause stroke (I610-I619, I630-I635, I638-I639, or I649), ischemic stroke (I630-I635 or I638-I639), and intracerebral haemorrhage (I610-I619) (Supplementary Table 3).

Variables for subgroup analyses

Patients with a diagnosis of hypertension before the ED visit were identified through a record of hypertension (I109) or a pick-up of a prescription of antihypertensive drugs within the preceding 12 months of the index visit. Antihypertensive drugs were defined according to the anatomic therapeutic classification (ATC) (Supplementary Table 4).

Follow-up period

The baseline for follow-up was defined as the time patients were discharged either from the ED or from inpatient care, in order to not include events during hospital care linked to the index visit and thereby avoid effects of an outcome occurring before the exposure. For patients that were not admitted to inpatient care but were directly discharged from the ED, one day was added after they were discharged, in order to avoid misclassification of a hospitalisation that had been referred to from the ED-visit.

Addressing potential bias

The risk of selection bias was minimised by the broad inclusion criteria for this study. BP categories were defined according to the clinically relevant definitions by the *ESC and ESH*.¹⁴

All outcomes were determined in advance with established definitions, disclosed in the trial registration at *clinicaltrials.gov*. The Swedish National Patient Register, from which the outcome data were obtained, has high validity.¹⁷

Statistical analysis

Hazard ratios (HR) for primary and secondary endpoints were estimated with Cox proportional hazard regression. Age, sex, inclusion year, and hospital were adjusted for in multivariate analyses. Age was controlled with restricted cubic splines with four knots in order to adjust for the gradually increasing impact of higher age on event rates. The reference BP categories in the analysis were set to the normal BP level according to *ESC and ESH* classification;¹⁴ SBP reference category was 120-129 mmHg, and DBP reference category was 80-84 mmHg. The proportional hazards assumption was evaluated by analysing Schoenfeld residuals. Subgroup analyses for the outcome ASCVD were performed with Cox proportional hazard regression for patients with a history of hypertension, for hospitalised patients, and by chief complaints. All chief complaints were categorised by medicine discipline based on the managing emergency department and type of chief complaint (Supplementary Table 5). Cumulative incidence functions for SBP categories were estimated for the endpoints with the Kaplan-Meier estimator. Cases with missing exposure and outcome data were excluded from the analyses. Descriptive statistics of the study population were presented as mean \pm standard deviation (SD) or relative and absolute frequencies grouped by SBP categories. A *p*-value of $<0,05$ was considered to be significant. STATA version 15.1 was used for the analysis. Participants with missing BP data or had an outcome before follow-up baseline were disregarded from the analysis.

To assess the potential benefit of screening for high BP among patients in the ED, a number needed to screen (NNS) and number needed to treat (NNT) were estimated for CHD, stroke,

and ASCVD. The estimates were based on the relative risk reduction (RRR) reported in previous research, where a 10-mmHg SBP reduction yielded a risk reduction by 22% for CHD and 14% for stroke, irrespectively of baseline BP.⁸ Potentially preventable events (PPE) per ED patient were calculated for all subjects with a SBP \geq 140 mmHg based on the RRR. PPE was weighted by the visits for each year, and NNS was derived by the inverse of the PPE per ED patient, presented with a 95% CI.

Patient and public involvement

Participants were not involved in the design of this study, nor the definition of exposures, outcome measures or the setting. Participants were not asked to advise on interpreting the data or contributed to writing the manuscript.

RESULTS

A total of 300,193 patients were included in the study after the inclusion criteria (Figure 1). The mean age was 50.0 \pm 20.2 years, female patients comprised 53.9% (n=161,707) of the study population, and the mean SBP was 139.9 mmHg (Table 1). Subjects were followed for a mean time of 3.5 years, which resulted in 1.1 million person-years. The most common chief complaint was abdominal pain, chest pain, breathing difficulties, headache, and fever. (Supplementary Table 5). SBP data were missing for 59 (0.02%) subjects, and 1,992 (0.67%) subjects had data missing for DBP. No subject were missing data for both SBP and DBP. Outcome data were obtained for all included participants.

Table 1. General characteristics of the study population.

	Systolic Blood Pressure (mmHg)							
	Total n=300,193	<90 n=1,524	90-119 n=52,493	120-129 n=51,667	130-139 n=55,012	140-159 n=80,770	160-179 n=37,207	≥180 n=21,379
Age								
Age, mean (SD), y	50.0 (20.2)	60.4 (21.6)	43.0 (19.3)	43.0 (18.5)	45.7 (18.9)	52.0 (19.5)	60.7 (17.8)	67.7 (14.8)
<65 No. (%)	219,189 (73.0)	748 (49.1)	43,684 (83.2)	43,790 (84.7)	44,685 (81.2)	57,354 (71.0)	20,433 (54.9)	8,391 (39.2)
65-74 No. (%)	38,121 (12.7)	314 (20.6)	3,729 (7.1)	3,689 (7.1)	5,020 (9.1)	11,487 (14.2)	8,121 (21.8)	5,757 (26.9)
>74 No. (%)	42,883 (14.3)	462 (30.3)	5,080 (9.7)	4,198 (8.1)	5,307 (9.6)	11,929 (14.8)	8,653 (23.3)	7,232 (33.8)
Sex								
Female, No. (%)	161,707 (53.9)	864 (56.7)	36,588 (69.7)	30,353 (58.7)	27,515 (50.0)	36,768 (45.5)	17,546 (47.2)	12,002 (56.1)
Blood Pressure								
SBP mean (SD), mmHg	139.9 (24.2)	80.4 (8.0)	110.1 (6.8)	123.9 (3.1)	133.9 (3.1)	147.6 (5.9)	167.4 (5.9)	194.6 (14.6)
DBP mean (SD), mmHg	80.8 (15.0)	54.9 (14.2)	68.5 (11.3)	75.0 (10.2)	79.2 (11.6)	84.6 (12.1)	91.0 (14.5)	98.7 (14.4)
Medical history								
Hypertension, No. (%)	75,385 (25.1)	663 (43.5)	7,977 (15.2)	7,410 (14.3)	9,728 (17.7)	21,915 (27.1)	15,551 (41.8)	12,111 (56.6)
Diabetes, No. (%)	20,526 (6.8)	152 (10.0)	2,353 (4.5)	2,282 (4.4)	3,017 (5.5)	6,075 (7.5)	3,962 (10.6)	2,675 (12.5)
CVD, No. (%)	13,732 (4.6)	164 (10.8)	1,941 (3.7)	1,638 (3.2)	1,959 (3.6)	3,893 (4.8)	2,388 (6.4)	1,747 (8.2)
Admission to inpatient care								
Admitted, No. (%)	76,390 (25.5)	989 (64.9)	13,836 (26.4)	11,293 (21.9)	12,071 (21.9)	19,861 (24.6)	10,858 (29.2)	7,460 (34.9)
Chief complaints by medical discipline								
Internal Medicine, No (%)	112,264 (37.4)	772 (50.7)	19,246 (36.7)	18,400 (35.6)	20,160 (36.6)	30,328 (37.5)	14,716 (39.6)	8,595 (40.2)
Surgery, No (%)	83,956 (28.0)	350 (23.0)	17,523 (33.4)	16,133 (31.2)	16,038 (29.2)	21,501 (26.6)	8,440 (22.7)	3,935 (18.4)
Otolaryngology, No (%)	13,622 (4.5)	46 (3.0)	1,832 (3.5)	2,163 (4.2)	2,688 (4.9)	3,580 (4.4)	1,938 (5.2)	1,379 (6.4)
Neurology, No (%)	37,071 (12.3)	79 (5.2)	4,785 (9.1)	5,729 (11.1)	6,401 (11.6)	10,626 (13.2)	5,486 (14.7)	3,956 (18.5)
Orthopaedics, No (%)	30,819 (10.3)	89 (5.8)	4,403 (8.4)	5,220 (10.1)	5,730 (10.4)	9,294 (11.5)	4,068 (10.9)	1,993 (9.3)
Unknown, No (%)	22,461 (7.5)	188 (12.3)	4,704 (9.0)	4,032 (7.8)	3,995 (7.3)	5,441 (6.7)	2,559 (6.9)	1,530 (7.2)

Abbreviations SBP = systolic blood Pressure. DBP = diastolic blood pressure. SD = standard deviation. No = number. y = years.

Incident ASCVD occurred in 3.0% (n=8,999) of the cohort during a median follow-up for 42 months (range 0-84 month). Men were more likely to develop ASCVD (3.7%) compared to females (2.4%). BP was associated with incident ASCVD with a progressively increased hazard ratio among patients with SBP above reference categories. Within SBP, the strongest association was observed for ≥ 180 mmHg (HR 1.63, 95% CI 1.49-1.77) (Table 2). The six-year cumulative incidence of ASCVD for the reference SBP group (120-129 mmHg) was 2% compared to 12% in the highest SBP category (≥ 180 mmHg) (Figure 2). A statistically significant increased association were observed in all categories above the reference category for DBP.

Table 2. Hazard ratio for ASCVD.

SBP (mmHg)	Crude			Adjusted ^a		
	HR	95% CI	p-value	HR	95% CI	p-value
<90	2.17	1.59 to 2.97	<0.0001	0.92	0.67 to 1.26	0.618
90-119	1.07	0.97 to 1.17	0.191	1.10	1.00- to .22	0.043
120-129 ^b	Reference			Reference		
130-139	1.30	1.19 to 1.42	<0.0001	1.05	0.96 to 1.15	0.257
140-159	2.08	1.92 to 2.25	<0.0001	1.15	1.06 to 1.24	0.001
160-179	3.57	3.29 to 3.88	<0.0001	1.35	1.25 to 1.47	<0.0001
≥ 180	5.45	5.01 to 5.93	<0.0001	1.63	1.49 to 1.77	<0.0001
DBP (mmHg)	HR	95% CI	p-value	HR	95% CI	p-value
<60	1.20	1.07 to 1.36	0.002	1.08	0.96 to 1.22	0.199
60-79	0.89	0.83 to 0.95	<0.0001	1.01	0.95 to 1.08	0.704
80-84 ^b	Reference			Reference		
85-89	1.20	1.11 to 1.30	<0.0001	1.13	1.05 to 1.23	0.002
90-99	1.43	1.33 to 1.53	<0.0001	1.15	1.07 to 1.23	<0.0001
100-109	1.94	1.79 to 2.11	<0.0001	1.40	1.29 to 1.52	<0.0001
≥ 110	2.61	2.36 to 2.88	<0.0001	1.71	1.55 to 1.89	<0.0001

^a Adjusted for age, sex, inclusion year, hospital.

^b Reference category for Cox proportional hazard analysis

Abbreviations ASCVD = atherosclerotic cardiovascular disease. SBP = systolic blood pressure. DBP = diastolic blood pressure. HR = hazard ratio. CI = confidence interval.

For the secondary endpoint MI, a total of 4,847 (1.6%) events occurred in the entire cohort, the majority 63.2% (n=3,117) among men. There was a statistically significant association between BP and incident MI with a gradually increased HR by higher BP above the reference category. (Figure 3-4). The six-year cumulative incidence was 1% for the reference category compared to 7% in the highest SBP group (Figure 5).

A total of 6,661 (2.2%) all-cause stroke events occurred, and of those were 51.0% male (n=3,470). Patients with DBP \geq 110 had more than a twofold association (HR 2.16, 95% CI 1.93-2.41) to a stroke event (Figure 4-5). The six-year cumulative incidence was 1% for the reference category compared to 9% in the highest SBP group (Figure 6).

For the endpoints ischemic stroke and intracerebral haemorrhage, a total of 5,355 respectively 1,119 events occurred. The highest HR for ischemic stroke was in the \geq 110 mmHg DBP category (HR 1.91, 95% CI 1.68-2.17). The strongest association for intracerebral haemorrhage was in the top DBP category (HR 3.56 95% CI 2.80-4.52) (Figure 4-5).

Subgroup analyses

Patients with a history of hypertension had 5,667 (7.6%) ASCVD events, compared to 3,300 (1.5%) for those without the condition (Supplementary Table 6). BP above the reference category had a progressively increased association with ASCVD regardless of previous hypertension. Patients with no prior hypertension diagnosis had a lower absolute event rate, but a stronger and steeper relative association with ASCVD compared to the hypertension group. The strongest association for ASCVD was in SBP \geq 180 mmHg, for patients with no history of hypertension (HR 2.02, 95% CI 1.75-2.33) (Figure 7).

A total of 76,474 patients (25.5%) were admitted to inpatient care and among these were 50.5% men. The admitted patients had 4,614 ASCVD events during the study period compared to 4,323 events for those who were directly discharged. The mean age for the

admitted patients were 60.0 ± 20.4 years and 46.5 ± 18.9 years for the other group. There was a progressively increased hazard ratio among patients with SBP in the categories above the reference group. The association was similar in the two groups in the adjusted model. (Figure 8).

The most common chief complaint was in the internal medicine discipline with 3,934 incident ASCVD events (Supplementary Table 7). There was a gradual association above the reference category between BP and incident ASCVD in all chief complaints except for the orthopaedics and otolaryngology disciplines. The strongest association for BP with ASCVD was in the surgery discipline in the crude model (HR 9.35, 95% CI 7.48-11.70). In the adjusted model, the strongest association with ASCVD were in the neurology discipline (Figure 9).

Number needed to screen

PPE was estimated to 1,966 ASCVD events, 672 CHD, 1,252 strokes. The estimated NNS to find high BP and to prevent one event for ASCVD, CHD and stroke, during a median of 42 months of follow-up, was 151 (95% CI 127-190), 442 (95% CI 360-572), and 157 (95% CI 134-195), respectively, whereas the NNT was estimated to 71, 208, and 112. For patients that were directly discharged, NNS for ASCVD was 216, whereas, NNT for high BP was estimated to 103. To prevent one fatal ASCVD event, 450 patients in the ED needed to be screened for high BP and 150 of those needed to be treated for high BP. (Table 3)

Table 3. Number needed to screen and treat to prevent CHD, stroke, and ASCVD. The estimates were based on the assumption that all detected patients with SBP ≥ 140 mmHg were treated with antihypertensive therapy.

Estimates for all patients	CHD	Stroke	ASCVD
Relative risk reduction. % (95% CI) ^a	22 (17 to 27)	41 (33 to 48)	32 (25 to 38)
PPE. No (95% CI)	672 (519 to 824)	1,252 (1,007 to 1,465)	1,966 (1,561 to 2,341)
PPE per ED patient. % (95% CI)	0.23 (0.17 to 0.28)	0.64 (0.51 to 0.75)	0.66 (0.53 to 0.79)
PPE per 1,000 ED patients. No (95% CI)	3 (2 to 3)	7 (6 to 8)	7 (6 to 8)
NNT. No (95% CI)	208 (170 to 269)	112 (96 to 139)	71 (60 to 90)
NNS. No (95% CI)	442 (360 to 572)	157 (134 to 195)	151 (127 to 190)
Estimates for directly discharged	CHD	Stroke	ASCVD
Relative risk reduction. % (95% CI) ^a	22 (17 to 27)	41 (33 to 48)	32 (25 to 38)
PPE. No (95% CI)	499 (385 to 612)	1,225 (986 to 1,435)	1,366 (1,084 to 1,626)
PPE per ED patient. % (95% CI)	0.17 (0.13 to 0.21)	0.42 (0.33 to 0.49)	0.46 (0.37 to 0.55)
PPE per 1,000 ED patients. No (95% CI)	2 (2 to 3)	5 (4 to 5)	5 (4 to 6)
NNT. No (95% CI)	280 (228 to 362)	114 (98 to 142)	103 (86 to 129)
NNS. No (95% CI)	591 (482 to 765)	241 (206 to 299)	216 (182 to 272)
Estimates for fatal events	CHD	Stroke	ASCVD
Relative risk reduction. % (95% CI) ^a	22 (17 to 27)	41 (33 to 48)	32 (25 to 38)
PPE. No (95% CI)	465 (359 to 571)	1,148 (924 to 1,344)	932 (740 to 1,109)
PPE per ED patient. % (95% CI)	0.16 (0.12 to 0.19)	0.29 (0.23 to 0.34)	0.22 (0.18 to 0.26)
PPE per 1,000 ED patients. No (95% CI)	2 (2 to 2)	3 (3 to 4)	3 (2 to 3)
NNT. No (95% CI)	300 (245 to 388)	122 (104 to 151)	150 (126 to 189)
NNS. No (95% CI)	644 (525 to 833)	346 (295 to 429)	450 (378 to 567)

^aRelative risk reduction based on 10-mmHg SBP reduction, as estimated by Law et al.⁸

Abbreviations CI: confidence interval. PPE: potentially preventable event. NNS: number needed to screen. NNT: number needed to treat. SBP: systolic blood pressure.

DISCUSSION

The main finding in this study was the strong association between BP recorded in the ED and incident ASCVD, irrespective of whether patients were admitted to inpatient care or had a history of hypertension. In patients without a history of hypertension, the association with incident ASCVD was stronger, than for those with an established diagnosis. By using effect sizes for antihypertensive treatment from meta-analysis⁸, we estimated that to prevent one future ASCVD event during a median of 42 months of follow-up, antihypertensive treatment needed to be initiated in 71 patients with an ED-measured SBP ≥ 140 mmHg.

The association with ASCVD was gradually increasing for BP levels that corresponded to hypertension grade 1, 2 and 3¹⁴ (Supplementary Table 1). Furthermore, a statistically significant association with incident ASCVD was observed for patients with DBP level in the high normal category. Our findings show that hypertension grades may be of interest for the ED setting, and ED-measured BP is of value not only to evaluate the acuity of the patient's health but also to identify patients at high risk for cardiovascular events in the long-term and therefore provides a tool to prevent them.

Previous population-based research has shown that an increase in SBP results in a substantially increased risk for cardiovascular events, irrespective of baseline BP.^{6,7} While findings in the present study also showed a strong association between BP and incident ASCVD, the magnitude of the effect was smaller in comparison to the population-based studies. Since the current study did not account for the regression dilution bias due to single BP measurements, our findings probably underestimate the true association between BP in the ED and incident ASCVD.¹⁸ The influence of different stressors, both related to acute disease and the ED environment, may cause an increase of BP in the ED, and elevated BP levels are commonly observed.⁴ Previously, the prognostic relevance of elevated BP in the ED, and if it can be a basis for decisions to initiate or intensify antihypertensive treatment in this setting

has been unknown. However, it should be noted that BP measured during other stress, such as exercise, previously have provided independent prognostic information regarding incident ASCVD.^{19,20} Although it can be speculated that different mechanisms influence BP in the ED and its association with ASCVD, which may explain some of the differences in this study compared to the population-based studies. Here we, for the first time, provide evidence that a first BP obtained in the ED among an unselected population with ED visitors is associated with incident ASCVD.

All secondary endpoints had similar results as for ASCVD. However, there was a remarkably strong association between $DBP \geq 110$ mmHg and incident intracerebral haemorrhage, in the adjusted model, which none of the previously population-based studies has reported.

Patients with a history of hypertension had a higher absolute risk to develop ASCVD, but interestingly the association between elevated BP and incident ASCVD was stronger for patients with no history of hypertension. A possible explanation may be that antihypertensive treatment used in the hypertension group attenuated the association.

The estimated NNS was based on the assumption that all detected patients with an $SBP \geq 140$ mmHg were prescribed adequate antihypertensive therapy and succeeded a 10-mmHg SBP-reduction. Prior research has presented a NNS for hypertension with BP-lowering actions,²¹ to the best of our knowledge none have reported the potential benefit of using BPs obtained in the ED with an estimated potential benefit of reduced events. Findings in this study indicate that the ED-setting has great potential to find undiagnosed and undertreated hypertension, which will reduce morbidity and mortality in CVD if effective antihypertensive therapy is initiated.

The main strength of this study was the large cohort size and the long follow-up period, which yielded a strong statistical power. The Swedish National Patient register is well-known for its high-quality and accurate data, with a high reported positive predictive value for most of the

diagnoses.¹⁷ It is noticeable that a few cases had missing data. One potential weakness in this study was the uncertainty of how BP was measured, and due to discrepancies in methods for obtaining BP, deviations for BP may vary from case to case. Preferred end-digits for BP by multiples of 5 and 10 were noticed in the data, which indicates that rounding occurred for some cases. The impact of the rounding was reduced by categorising the BP into groups. Another limitation is that any changes in antihypertensive treatment that were initiated based on elevated ED-measured BP were not considered. Such treatment may have attenuated the association with incident ASCVD and therefore underestimated the true association.

We encourage future studies to investigate whether initiation of antihypertensive treatment in the ED yield better long-term prognosis for patients with elevated ED-recorded BP, compared to current praxis.

The clinical value of the findings in this study is that ED-measured BP has a great potential to find undiagnosed hypertension and to prevent future ASCVD events if antihypertensive therapy is initiated. Patients directly discharged from the ED should be assessed more carefully as no further BP recordings take place. One ASCVD event could be prevented for every 107 discharged patients with a high BP if effective antihypertensive therapy is initiated. Thereby, high BP recordings should not be disregarded as isolated events but should result in an initiation of antihypertensive treatment or referral for follow-up evaluation. It is conceivable that the external validity of this study applies to other EDs, particularly considering the broad inclusion criteria, which included all Swedish citizens ≥ 18 years old with a BP obtained in the ED.

In conclusion, findings in this study show that elevated BP, when measured in the ED, is strongly associated with incident ASCVD, MI, and stroke. High BP recordings in EDs should not be disregarded as isolated events, but an opportunity to detect and improve treatment of hypertension. ED-measurements of BP provide an important and under-used tool with great

potential to reduce morbidity and mortality associated with hypertension.

FOOTNOTES

Contributions

PS conducted the study, acquired all data and the ethical permit from the Regional Ethical Review Board in Stockholm. PO wrote the manuscript, supervised by PS and supported by PHS and HH. HH performed the statistical analysis. HH, PO and PS interpreted the data. PO and HH produced all figures. All authors critically revised the manuscript for intellectual content and approved the final version of the report. The corresponding author had access to all data in this study and is responsible for the decision to submit this study.

Ethical approval

This study has been approved by the Regional Ethical Review Board in Stockholm, without the requirement of informed consent. Ethical review number 2016/888-31.

Competing interests

The authors received no support from any organisation for this study; no financial relationship with any organisation that may have an interest in this work in the previous 36 months; no other relationship or activities that could appear to have influenced the submitted work.

Funding

The authors received no financial support for the study, authorship, and publication of this report.

Transparency declaration

The guarantor (PS) affirms that this manuscript is an honest, accurate and transparent account of the study being reported; and that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

Data sharing

No additional data are available

SUMMARY

What is already known on this topic

- Hypertension is the leading risk factor for CVD and remains a global challenge in prevention, detection, and improving treatment.
- Antihypertensive treatment reduces the risk of incident ASCVD.
- BP is recorded in most patients in the ED, but the predictive value of BP recorded in the ED for the long-term prognosis is unknown. It is not known whether elevated BP in the ED is associated with ASCVD, MI or stroke.

What this study adds

- This is the first study to report the association between ED-recorded BP and long-term incident cardiovascular diseases.
- Elevated BP in the ED is progressively associated with incident ASCVD, MI and stroke, for BP levels above normal (SBP: ≥ 140 mmHg and DBP: ≥ 90 mmHg)
- The six-year cumulative incidence of ASCVD in SBP ≥ 180 was 12%, compared to 2% for the normal SBP.

- To prevent one ASCVD event, during a median of 42 months of follow-up, the number needed to screen for high BP in the ED was 151, whereas the number needed to treat with antihypertensive treatment was estimated to 71 patients.
- ED-measurements of BP provide an important and under-used tool with great potential to reduce morbidity and mortality associated with hypertension.

REFERENCES

1. Staessen JA, Wang J, Bianchi G, Birkenhäger WH. Essential hypertension. *Lancet* 2003; **361**(9369): 1629-41.
2. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. *Arch Intern Med* 1993; **153**(5): 598-615.
3. Flint AC, Conell C, Ren X, et al. Effect of Systolic and Diastolic Blood Pressure on Cardiovascular Outcomes. *N Engl J Med* 2019; **381**(3): 243-51.
4. Backer HD, Decker L, Ackerson L. Reproducibility of increased blood pressure during an emergency department or urgent care visit. *Ann Emerg Med* 2003; **41**(4): 507-12.
5. WHO. A Global brief on hypertension. 2013. http://ish-world.com/downloads/pdf/global_brief_hypertension.pdf (accessed January 30 2019).
6. Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. *Lancet* 2014; **383**(9932): 1899-911.
7. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 2002; **360**(9349): 1903-13.
8. Law M, Morris J, Wald N. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ* 2009; **338**.
9. Ferdinand KC, Nasser SA. Management of Essential Hypertension. *Cardiol Clin* 2017; **35**(2): 231-46.
10. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension* 2003; **42**(6): 1206-52.
11. Skoglund P, Svensson P. Asking the Patient or Measuring Blood Pressure in the Emergency Department: Which One is Best? *Curr Hypertens Rep* 2016; **18**(7).
12. Swedish Council on Health Technology Assessment. Triage and flow in the Emergency

- Department: A systematic literature review [Internet]. 2010.
https://www.ncbi.nlm.nih.gov/books/NBK447967/pdf/Bookshelf_NBK447967.pdf
(accessed February 1 2019).
13. Chernow SM, Iserson KV, Criss E. Use of the emergency department for hypertension screening: a prospective study. *Ann Emerg Med* 1987; **16**(2): 180-2.
 14. Williams B, Mancia G, Spiering W, et al. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. *J Hypertens* 2018; **36**(12): 2284-309.
 15. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2014; **63**(25 Pt B): 2935-59.
 16. WHO. International Classification of Diseases (ICD). 2018.
<http://www.who.int/classifications/icd/en/> (accessed January 31 2019).
 17. Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. *BMC public health* 2011; **11**.
 18. Hutcheon J, Chiolero A, Hanley J. Random measurement error and regression dilution bias. *BMJ* 2010; **340**: c2289.
 19. Kurl S, Laukkanen JA, Rauramaa R, Lakka TA, Sivenius J, Salonen JT. Systolic blood pressure response to exercise stress test and risk of stroke. *Stroke* 2001; **32**(9): 2036-41.
 20. Kjeldsen SE, Mundal R, Sandvik L, Erikssen G, Thaulow E, Erikssen J. Supine and exercise systolic blood pressure predict cardiovascular death in middle-aged men. *J hypertens* 2001; **19**(8): 1343-8.
 21. Rembold CM. Number needed to screen: development of a statistic for disease screening. *BMJ* 1998; **317**(7154): 307-12.





Figure 1. Flowchart of patient selection.



No at risk

Total	299,170	271,135	221,865	172,344	123,763	71,737	35,126
<90	1,419	1,048	837	695	522	337	163
90-119	52,247	47,011	39,041	30,897	22,919	14,111	7,038
120-129	51,577	47,459	39,142	30,626	22,318	13,395	6,581
130-139	54,917	50,354	40,819	30,977	22,119	12,438	6,087
140-159	80,634	73,393	60,281	47,215	33,524	19,225	9,430
160-179	37,114	33,243	26,915	20,638	14,586	8,122	3,916
≥180	21,262	18,627	14,830	11,296	7,775	4,109	1,911

Figure 2. Cumulative incidence of ASCVD. Cumulative incidence are presented by SBP categories. Number at risk presents the number of subjects entering each interval.

^a Reference category for Cox proportional hazard regression

Abbreviations ASCVD: atherosclerotic cardiovascular disease. SBP: systolic blood pressure




Figure 3. Hazard ratio for primary and secondary outcomes. HR, 95% CI and p-value presented by SBP categories in a crude and adjusted model.

^a Adjusted for age, sex, inclusion year, hospital.

^b Reference category for Cox proportional hazard regression

Abbreviations ASCVD: atherosclerotic cardiovascular disease. CI: confidence interval. CHD: coronary heart disease. ICH: intracerebral hemorrhage. HR: hazard ratio. MI: myocardial infarction. SBP: systolic blood pressure





Figure 4. Hazard ratio for primary and secondary outcomes. HR, 95% CI and p-value presented by DBP categories in a crude and adjusted model.

^a Adjusted for age, sex, inclusion year, hospital.

^b Reference category for Cox proportional hazard regression

Abbreviations ASCVD: atherosclerotic cardiovascular disease. CI: confidence interval. CHD: coronary heart disease. DBP: diastolic blood pressure ICH: intracerebral hemorrhage. HR: hazard ratio. MI: myocardial infarction.




No at risk

Total	299,158	273,092	224,096	174,487	125,598	73,018	35,813
<90	1,418	1,057	847	703	527	341	165
90-119	52,246	47,180	39,234	31,072	23,072	14,224	7,102
120-129	51,576	47,622	39,332	30,811	22,490	13,517	6,653
130-139	54,916	50,576	41,074	31,234	22,327	12,592	6,176
140-159	80,630	73,943	60,904	47,811	34,067	19,610	9,628
160-179	37,111	33,670	27,420	21,138	14,985	8,391	4,057
≥180	21,261	19,044	15,285	11,718	8,130	4,343	2,032

Figure 5. Cumulative incidence of MI. Cumulative incidence are presented by SBP categories. Number at risk presents the number of subjects entering each interval.

^a Reference category for Cox proportional hazard regression

Abbreviations MI: myocardial infarction. SBP: systolic blood pressure



No at risk

Total	299,191	271,881	222,945	173,601	124,974	72,664	35,652
<90	1,448	1,049	840	695	524	338	162
90-119	52,245	47,088	39,128	30,991	23,004	14,184	7,083
120-129	51,577	47,526	39,218	30,735	22,434	13,479	6,626
130-139	54,917	50,447	40,950	31,134	22,293	12,571	6,165
140-159	80,631	73,637	60,631	47,637	33,903	19,521	9,599
160-179	37,112	33,420	27,185	20,935	14,863	8,318	4,036
≥180	21,261	18,714	14,993	11,474	7,953	4,253	1,981

Figure 6. Cumulative incidence of all-cause stroke. Cumulative incidence are presented by SBP categories. Number at risk presents the number of subjects entering each interval.

^a Reference category for Cox proportional hazard regression

Abbreviations SBP: systolic blood pressure




Figure 7. Comparison of hazard ratio for ASCVD by hypertension and non-hypertension groups. HR, 95% CI and p-value presented by SBP categories in a crude and adjusted model.

^a Adjusted for age, sex, inclusion year, hospital.

^b Reference category for Cox proportional hazard regression

Abbreviations ASCVD: atherosclerotic cardiovascular disease. CI: confidence interval. HR: hazard ratio.




Figure 8. Comparison of hazard ratio for ASCVD by admitted and directly discharged patients. HR, 95% CI and p-value presented by SBP categories in a crude and adjusted model.

^a Adjusted for age, sex, inclusion year, hospital.

^b Reference category for Cox proportional hazard regression

Abbreviations ASCVD: atherosclerotic cardiovascular disease. CI: confidence interval. HR: hazard ratio.





Figure 9. Hazard ratio for ASCVD by chief complaints. HR, 95% CI and p-value presented by SBP categories in a crude and adjusted model.

^a Adjusted for age, sex, inclusion year, hospital.

^b Reference category for Cox proportional hazard regression




No at risk

Total	297,247	269,493	220,646	171,550	123,448	71,655	35,082
<60	11,928	10,023	8,033	6,054	4,263	2,387	1,099
60-79	124,876	112,824	91,945	70,418	49,840	28,093	13,511
80-84	51,297	46,988	38,685	30,403	22,185	13,076	6,439
85-89	34,464	31,570	25,881	20,150	14,378	8,371	4,098
90-99	47,934	43,921	36,060	28,526	20,931	12,359	6,109
100-109	18,976	17,205	14,264	11,402	8,374	5,179	2,658
≥110	7,772	6,962	5,778	4,597	3,477	2,190	1,168

Supplementary Figure 1. Cumulative incidence of ASCVD. Cumulative incidence are presented by DBP categories. Number at risk presents the number of subjects entering each interval.

^a Reference category for Cox proportional hazard regression

Abbreviations DBP: diastolic blood pressure




No at risk

Total	297,235	271,343	222,861	173,686	125,278	72,936	35,769
<60	11,927	10,084	8,101	6,118	4,313	2,424	1,118
60-79	124,872	113,394	92,626	71,061	50,395	28,437	13,690
80-84	51,295	47,273	39,008	30,726	22,449	13,261	6,529
85-89	34,463	31,808	26,151	20,417	14,618	8,556	4,204
90-99	47,930	44,308	36,507	28,952	21,304	12,634	6,261
100-109	18,976	17,445	14,526	11,662	8,606	5,340	2,747
≥110	7,772	7,122	5,942	4,750	3,593	2,284	1,220

Supplementary Figure 2. Cumulative incidence of MI. Cumulative incidence are presented by DBP categories. Number at risk presents the number of subjects entering each interval.

^a Reference category for Cox proportional hazard regression

Abbreviations MI: myocardial infarction. DBP: diastolic blood pressure



No at risk

Total	297,238	270,238	221,725	172,801	124,656	72,582	35,608
<60	11,926	10,064	8,082	6,093	4,300	2,409	1,109
60-79	124,875	113,053	92,251	70,801	50,189	28,363	13,654
80-84	51,295	47,104	38,834	30,579	22,351	13,209	6,512
85-89	34,463	31,666	26,038	20,328	14,551	8,481	4,165
90-99	47,931	44,103	36,331	28,829	21,213	12,570	6,237
100-109	18,976	17,288	14,382	11,536	8,518	5,302	2,726
≥110	7,772	6,960	5,807	4,635	3,534	2,248	1,205

Supplementary Figure 3. Cumulative incidence of all-cause stroke. Cumulative incidence are presented by DBP categories. Number at risk presents the number of subjects entering each interval.

^a Reference category for Cox proportional hazard regression

Abbreviations DBP: diastolic blood pressure